Technology/Life Sciences

Practice Group

ABOUT

Companies in the technology/life sciences space are in the business of improving and saving lives through innovative procedures and advanced technology. With an industry that includes everything from clean tech and software start-ups to major, multinational pharmaceutical companies, risks vary widely and require specialized and individualized attention.

Formed in 2020, Assurex Global’s Technology/Life Sciences Practice Group brings together the foremost technology/life sciences insurance experts to share their knowledge, experience and negotiating power to develop new products, programs, and service models.

For technology/life sciences professionals, this means doing business with our Partners delivers effectively managed risk and a better bottom line.

Carrier Engagement
Our Partners enjoy enhanced access and engagement with the top insurance carriers in the technology/life science industry.
Dedicated Staff
Every Partner has dedicated sales and service staff in the technology/life science industry.
Benchmark Report
We deliver an annual benchmark report and support collateral based on real customer data.
Best Practices
Our Partners collaborate to share industry leading best practices.

Insurance Program
We have developed insurance programs specifically designed for the technology/life science industry and sponsored by key insurance carriers.
Partner Collaboration
Our Partners collaborate worldwide to understand and then properly write business on a local level.
Intellectual Capital
We constantly share knowledge and discuss latest exposures, claims experience, and industry trends.
Education
Our Partners have industry-specific training and insurance certification.

Life Sciences Solutions

Inadequate insurance coverage can put your entire mission at risk

You know that you make a change that will better human life. When your company is standing on the forefront of blazing a new solution in the life sciences industry, your company can still be at the whim of critical R&D investments, rigorous clinical trials, access to capital and ongoing regulatory hurdles.

Learn More